Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, Mineralys Therapeutics Inc’s stock clocked out at $13.46, up 0.37% from its previous closing price of $13.41. In other words, the price has increased by $0.37 from its previous closing price. On the day, 0.58 million shares were traded. MLYS stock price reached its highest trading level at $13.69 during the session, while it also had its lowest trading level at $13.105.
Ratios:
To gain a deeper understanding of MLYS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 26.48 and its Current Ratio is at 26.48. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on June 11, 2025, initiated with a Hold rating and assigned the stock a target price of $15.
On July 10, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30.
On April 02, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $30.Goldman initiated its Buy rating on April 02, 2024, with a $30 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jul 30 ’25 when Levy Adam Scott sold 59,925 shares for $14.76 per share. The transaction valued at 884,372 led to the insider holds 132,934 shares of the business.
Levy Adam Scott sold 12,946 shares of MLYS for $181,803 on Jul 28 ’25. The CFO and Secretary now owns 193,666 shares after completing the transaction at $14.04 per share. On Jul 29 ’25, another insider, Levy Adam Scott, who serves as the CFO and Secretary of the company, sold 807 shares for $14.00 each. As a result, the insider received 11,302 and left with 192,859 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MLYS now has a Market Capitalization of 877259520 and an Enterprise Value of 534233376.
Stock Price History:
The Beta on a monthly basis for MLYS is -0.26, which has changed by 0.2050134 over the last 52 weeks, in comparison to a change of 0.19283521 over the same period for the S&P500. Over the past 52 weeks, MLYS has reached a high of $18.38, while it has fallen to a 52-week low of $8.24. The 50-Day Moving Average of the stock is -6.71%, while the 200-Day Moving Average is calculated to be 2.40%.
Shares Statistics:
It appears that MLYS traded 804.23K shares on average per day over the past three months and 695340 shares per day over the past ten days. A total of 64.88M shares are outstanding, with a floating share count of 40.71M. Insiders hold about 37.54% of the company’s shares, while institutions hold 64.90% stake in the company. Shares short for MLYS as of 1752537600 were 7867965 with a Short Ratio of 9.78, compared to 1749772800 on 6168786. Therefore, it implies a Short% of Shares Outstanding of 7867965 and a Short% of Float of 15.950000000000001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Current recommendations for the stock of the company come from 7.0 analysts. The consensus estimate for the next quarter is -$0.73, with high estimates of -$0.52 and low estimates of -$0.92.
Analysts are recommending an EPS of between -$2.36 and -$4.16 for the fiscal current year, implying an average EPS of -$3.09. EPS for the following year is -$3.13, with 7.0 analysts recommending between -$2.15 and -$4.3.
